J. Rajković

SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives

Heart failure (HF) remains a major clinical and public health challenge despite advances in guideline‐directed therapy. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have transformed HF management by reducing worsening HF events across the spectrum of left ventricular ejection fraction, irrespective of diabe...